Reading time: 4 minutes Mia Hubert Chronic myelogenous leukemia (CML) is a slow-progressing disease resulting from an overproduction of blood cells originating from the bone marrow, known as myeloid cells. Before 2001, the standard of care included chemotherapy and bone marrow transplantation (BMT). Unfortunately, chemotherapeutic approaches were non-curative and BMT entailed a high-risk procedure with... Continue Reading →
Significance of Minimal Residual Disease Reading time: 3 minutes Aishwarya Subramanian Leukemia is a condition in which the number of white blood cells increase because of malfunctions in blood-forming tissues. White blood cells that provide immunity to the body and protect it from diseases undergo genetic alterations and mutations causing them to undergo rapid division.... Continue Reading →
Reading time: 4 minutes Alex S. Woodell In my previous article, we weathered the cytokine storm, a deadly immune response that can occur following chimeric antigen receptor T cell (CAR-T) therapy. Despite this risk, CAR-T therapy is quite effective in treating blood cancers such as acute lymphoblastic leukemia (ALL). Unfortunately, not all patients respond favorably... Continue Reading →
Taylor B. Poston Childhood acute leukemia is the most common pediatric cancer in the developed world. It accounts for one-third of all cases and affects 1 in 2000 children under the age of 15. More specifically, acute lymphoblastic leukemia (ALL) is the most common pediatric leukemia and case numbers have been increasing steadily at 1%... Continue Reading →
Manisit Das Since the beginning of OncoBites, we’ve talked a lot about immunotherapy: using our own immune cells to destroy the cancer cells? We can’t get enough of it! In one post, we highlighted a revolutionary approach recently approved by the US Food and Drug Administration (FDA) using genetically modified immune cells to fight cancer,... Continue Reading →
OncoBites 